Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma
RZV demonstrated strong immunogenicity and acceptable safety in CLL and MM patients, significantly boosting IgG levels, even in actively treated or heavily pretreated patients.
Authors
- Georgios Kyriakakis
- Panagiotis Diamantopoulos (ORCID: https://orcid.org/0000-0003-2692-5944)
- Stavroula Smilakou
- Stavroula Syriopoulou
- Dimitra Vlachopoulou
- Vassiliki Labropoulou (ORCID: https://orcid.org/0000-0002-9247-6617)
- Christos Stafylidis (ORCID: https://orcid.org/0000-0003-3918-4401)
- Marina Mantzourani (ORCID: https://orcid.org/0000-0001-5606-5303)
- Amalia Anastasopoulou (ORCID: https://orcid.org/0000-0002-2147-7583)
- Christina‐Nefeli Kontandreopoulou (ORCID: https://orcid.org/0000-0003-4721-0809)
- Iraklis Patsialos
- Anastasios Vogiatzakis
- Eleni Panousi
- Alexandros Gkikas
- Eleftherios N. Athanasopoulos
Institutions
- University of Patras (GR)
- National and Kapodistrian University of Athens (GR)
- Laiko General Hospital of Athens (GR)
Publication Details
- Journal
- Vaccines
- Published
- 2024-10-25
- DOI
- https://doi.org/10.3390/vaccines12111216
- Citations
- 2
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.77